Novartis Ag

Ludwig Institute for Cancer Research Limited

Licentia, Ltd.

Arne Östman

Carl-Henrik Heldin

Kari Alitalo

Peter Traxler

Terence O'Reilly

Markus Wartmann

John David Rothermel

Ralf Brandt

Elisabeth Buchdunger

Kristian Pietras

Olli Leppänen

Seppo Ylā-Herttuala

The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.

Combination comprising a signal transduction inhibitor and an epothilone derivative

The invention relates to a combination of (a) an inhibitor of platelet-derived growth factor (PDGF) activity and (b) a vector for vascular endothelial growth factor (VEGF-, especially VEGF-C) gene transfer, a pharmaceutical preparation comprising (a) and (b) in combination together with a pharmaceutically acceptable carrier material; a product comprising (a) and (b) as defined above and optionally a pharmaceutically acceptable carrier material, for simultaneous, chronologically staggered or separate use; a method of administering or the use of said combination or product for the treatment of endothelial damage; and/or to the use of (a) and (b) for the manufacture of said pharmaceutical preparation or product for the treatment of endothelial damage.

Combination for the treatment of endothelial damage

Growing community of inventors

Uppsala, Sweden

Arne Östman